Premium
Private equity firm Advent International is set to strike its second deal within a year for a controlling stake in a drugmaker, indicating sustained investor interest in the sector as the world grapples with a health crisis. The American PE firm is the front-runner to acquire RA Chem Pharma Ltd after ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
